Mode
Text Size
Log in / Sign up
N/A N=80 Randomized Single-blind Treatment

Waitlist-Control Trial of Smartphone Cognitive Behavioral Therapy (CBT) for Body Dysmorphic Disorder (BDD)

Body Dysmorphic Disorder

Enrolled (actual)
80
Serious AEs
0.0%
Results posted
Sep 2022
Primary outcome: Primary: Difference in BDD Severity (BDD-YBOCS) at the End of Treatment/Waitlist Period. — 29.85; 30.85; 23.77; 27.13 score on a scale — p=<.0001

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Smartphone-delivered cognitive behavioral therapy (CBT) for body dysmorphic disorder (BDD) (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Massachusetts General Hospital
Primary completion
Jun 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Difference in BDD Severity (BDD-YBOCS) at the End of Treatment/Waitlist Period.
29.85; 30.85; 23.77; 27.13; 16.81; 26.70 <.0001 sig
SECONDARY
Difference in Depression at the End of Treatment/Waitlist Period
11.13; 11.43; 10.15; 10.08; 7.11; 10.31 0.0023 sig
SECONDARY
Difference in Delusionality at the End of Treatment/Waitlist Period
15.10; 14.45; 12.26; 13.50; 8.30; 13.22 <.0001 sig
SECONDARY
Difference in Functional Impairment at the End of Treatment/Waitlist Period
15.95; 17.08; 11.09; 13.22; 7.64; 13.49 .0008 sig
SECONDARY
Difference in Quality of Life at the End of Treatment/Waitlist Period
52.72; 48.35; 53.99; 52.12; 66.45; 55.20 .0011 sig

Summary

The investigators are testing the efficacy of Smartphone-delivered cognitive behavioral therapy (CBT) treatment for body dysmorphic disorder (BDD). The investigators hypothesize that participants receiving app-CBT will have greater improvement in body dysmorphic disorder symptom severity than those in the waitlist condition at treatment endpoint (week 12).

Eligibility Criteria

Inclusion Criteria

  • at least 18 years of age
  • current diagnosis of primary body dysmorphic disorder (BDD), based on a clinical structured diagnostic interview
  • currently living in the United States

Exclusion Criteria

  • Psychotropic medication changes within 2 months prior to enrollment (Participants taking psychotropic medication must have been on a stable dose for at least 2 months prior to enrollment and not change medication during study period)
  • Past participation in 4+ sessions of cognitive behavioral therapy (CBT) for body dysmorphic disorder (BDD)
  • Current severe substance use disorder
  • Lifetime bipolar disorder or psychosis
  • Acute, active suicidal ideation as indicated by clinical judgment and/or a score >2 on the suicidal ideation subscale of the Columbia-Suicide Severity Rating Scale (C-SSRS).
  • Current severe comorbid major depression, as indicated by clinical judgment and/or a Quick Inventory of Depressive Symptomatology- Self Report (QIDS-SR) total score ≥ 21
  • Concurrent psychological treatment
  • Does not own a supported Smartphone with a data plan
  • Lack of technology literacy that would interfere with ability to engage with smartphone treatment
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03673046). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search